Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-01597 | Ladiratuzumab vedotin | |
| Ladiratuzumab vedotin is an antibody-drug conjugate consisting of a humanized anti-LIV-1 IgG1 conjugated with monomethyl auristatin E (MMAE). Ladiratuzumab vedotin has the potential for the treatment ... | Inquiry | |
| BADC-01598 | Anetumab-MMAE | |
| Anetumab-MMAE is an antibody-drug conjugate consisting of an anti-MSLN monoclonal antibody and monomethyl auristatin E (MMAE). MMAE is an antimitotic agent that inhibits tubulin polymerization. | Inquiry | |
| BADC-01599 | Anetumab ravtansine | 1375258-01-7 |
| Anetumab ravtansine is an antibody-drug conjugate consisting of an anti-MSLN monoclonal antibody and the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential for the treatment of ... | Inquiry | |
| BADC-01600 | Sirtratumab vedotin | 1824663-83-3 |
| Sirtratumab vedotin is an antibody-drug conjugate consisting of a SLITRK6-specific human antibody conjugated to MMAE via a protease-cleavable linker. Sirtratumab vedotin has the potential for the trea... | Inquiry | |
| BADC-01601 | Tusamitamab ravtansine | 2254086-60-5 |
| Tusamitamab ravtansine is an antibody-drug conjugate consisting of an anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) antibody conjugated to the potent cytotoxic antitubulin D... | Inquiry | |
| BADC-01602 | Trastuzumab deruxtecan | 1826843-81-5 |
| Trastuzumab deruxtecan is an antibody-drug conjugate consisting of humanized anti-HER2 antibody and a topoisomerase I inhibitor payload. Trastuzumab deruxtecan has been used in the research of HER2 ex... | Inquiry | |
| BADC-01603 | Sacituzumab govitecan | 1491917-83-9 |
| Sacituzumab govitecan is an antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer. | Inquiry | |
| BADC-01604 | Disitamab vedotin | 2136633-23-1 |
| Disitamab vedotin is an antibody-drug conjugate consisting of the novel humanized anti-HER2 antibody (hertuzumab) conjugated to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin... | Inquiry | |
| BADC-01605 | Telisotuzumab vedotin | 1714088-51-3 |
| Telisotuzumab vedotin is a c-Met-targeted antibody and MMAE drug conjugate. Telisotuzumab vedotin has the potential for advanced non-small cell lung cancer treatment. | Inquiry | |
| BADC-01606 | Polatuzumab vedotin | 1313206-42-6 |
| Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. Polatuzumab vedotin has been approved for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL). | Inquiry | |
| BADC-01607 | Belantamab mafodotin | 2050232-20-5 |
| Belantamab mafodotin is an antibody-drug conjugate consisting of an antibody targeting B-cell maturation antigen (BCMA) conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF). Belantam... | Inquiry | |
| BADC-01608 | Loncastuximab tesirine | 1879918-31-6 |
| Loncastuximab tesirine is an anti-CD19 antibody-drug conjugate. Loncastuximab tesirine has been used in the research of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). | Inquiry | |
| BADC-01609 | Patritumab deruxtecan | 2227102-46-5 |
| Patritumab deruxtecan is an antibody-drug conjugate consisting of a human anti-HER3 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable link... | Inquiry | |
| BADC-01610 | Tisotumab vedotin | 1418731-10-8 |
| Tisotumab vedotin is an antibody-drug conjugate comprising a fully human monoclonal antibody specific for tissue factor (TF-011) conjugated to monomethyl auristatin E (MMAE). Tisotumab vedotin has bee... | Inquiry | |
| BADC-01611 | Farletuzumab ecteribulin | 2407465-18-1 |
| Farletuzumab ecteribulin is an antibody-drug conjugate consisting of the humanized antifolate receptor-alpha (FRα) monoclonal antibody conjugated to eribulin by a cathepsin B-cleavable linker. | Inquiry | |
| BADC-01612 | Moxetumomab pasudotox | 1020748-57-5 |
| Moxetumomab pasudotox is a recombinant immunotoxin composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38-kDa fragment of Pseudomonas exotoxin A, called PE38. Moxetumomab pasudo... | Inquiry | |
| BADC-01613 | Zilovertamab vedotin | |
| Zilovertamab vedotin is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) targeting antibody-drug conjugate consisting of zilovertamab, a proteolytically cleavable linker, and the antimicrotubu... | Inquiry | |
| BADC-01614 | Glembatumumab vedotin | 1182215-65-1 |
| Glembatumumab vedotin is an antibody-drug conjugate consisting of a fully human IgG2 monoclonal antibody (CR011) against gpNMB conjugated to the microtubule inhibitor, monomethyl auristatin E (MMAE). ... | Inquiry | |
| BADC-01615 | Trastuzumab duocarmazine | 1642152-40-6 |
| Trastuzumab duocarmazine is a HER2-targeting antibody-drug conjugate comprised of trastuzumab bound to a linker drug containing duocarmycin. Trastuzumab duocarmazine has been used in the research of H... | Inquiry | |
| BADC-01616 | Cantuzumab ravtansine | 868747-45-9 |
| Cantuzumab ravtansine is an antibody-drug conjugate comprised of a humanized monoclonal antibody cantuzumab (huC242) linked to a cytotoxic agent, ravtansine (DM4). | Inquiry |
